World's Best Scientists 2026 revealed!
Stephan Stilgenbauer

Stephan Stilgenbauer

D-Index & Metrics

Medicine

D-Index
133
Citations
81634
World Ranking
2191
National Ranking
108

Overview

Stephan Stilgenbauer is affiliated with the University of Ulm in Germany and has contributed extensively to the field of medicine, particularly focusing on chronic lymphocytic leukemia (CLL) and related hematological conditions.

Their research spans several subfields, including genetics, pathology and forensic medicine, immunology, oncology, and molecular biology. These areas reflect a broad investigation of disease mechanisms and therapeutic approaches within hematology and oncology.

Major topics covered in their work include:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Advanced Breast Cancer Therapies
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research
  • Acute Lymphoblastic Leukemia research

Stilgenbauer's frequent publication venues highlight their active presence in key medical journals, particularly those focused on hematology and oncology:

  • Blood
  • HemaSphere
  • Leukemia
  • Hematological Oncology
  • Haematologica

The scientist has collaborated regularly with several coauthors, indicating strong professional networks in hematology research. Frequent collaborators include Eugen Tausch, Michael Hallek, Kirsten Fischer, Christof Schneider, and Barbara Eichhorst.

Key publications by Stilgenbauer or with contributions in relation to their research field include:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial, 2020, The Lancet Oncology
  • First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia, 2023, New England Journal of Medicine
  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial, 2022, Leukemia
  • International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia, 2020, Blood

Best Publications

  • Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    Hartmut Döhner;Stephan Stilgenbauer;Axel Benner;Elke Leupolt

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • The landscape of genomic alterations across childhood cancers

    Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter

  • Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances

    Sabina Solinas-Toldo;Stefan Lampel;Stephan Stilgenbauer;Jeremy Nickolenko

  • Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer

  • Mutations driving CLL and their evolution in progression and relapse.

    Dan A. Landau;Eugen Tausch;Amaro N. Taylor-Weiner;Chip Stewart

  • VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia

    Alexander Kröber;Till Seiler;Till Seiler;Axel Benner;Axel Benner;Lars Bullinger;Lars Bullinger

  • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

    Hartmut Döhner;Konstanze Fischer;Martin Bentz;Katrin Hansen

  • Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

    Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Kirsten Fischer;Othman Al-Sawaf;Jasmin Bahlo;Anna Maria Fink

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • From pathogenesis to treatment of chronic lymphocytic leukaemia

    Thorsten Zenz;Daniel Mertens;Ralf Küppers;Hartmut Döhner

  • TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

    Thorsten Zenz;Barbara Eichhorst;Raymonde Busch;Tina Denzel

  • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

    Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

Frequent Co-Authors

Hartmut Döhner
Hartmut Döhner University of Ulm
Michael Hallek
Michael Hallek University of Cologne
Peter Lichter
Peter Lichter German Cancer Research Center
Michael Kneba
Michael Kneba Kiel University
Raymonde Busch
Raymonde Busch Technical University of Munich
Peter Hillmen
Peter Hillmen St James's University Hospital
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Axel Benner
Axel Benner German Cancer Research Center
Lars Bullinger
Lars Bullinger Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine can start with many different online degree programs. For those interested in advanced patient care, becoming a nurse practitioner is a popular and flexible route. Many accredited institutions offer programs specifically designed for working professionals, and finding the cheapest online np programs can make this path more accessible.

Another common entry point is earning a Bachelor of Science in Nursing (BSN). There are numerous reputable options for the cheapest online bsn programs that let students complete coursework at their own pace, while managing other life responsibilities.

Individuals who already hold an RN license might consider transitioning to a BSN for greater career prospects. Researching what is the cheapest rn to bsn program online can help maximize value without sacrificing quality or accreditation.

For those aiming for roles in research, teaching, or leadership, pursuing a phd in nursing through online study is an efficient way to advance. With affordable and flexible programs now widely available, online nursing education offers diverse pathways to complement your medical ambitions.

Best Scientists Citing Stephan Stilgenbauer

Trending Scientists

Recently Published Articles